Richardo D. Parrondo, MD

Key opinion leaders examine recent evidence on acquired BTK inhibitor resistance in chronic lymphocytic leukemia and analyze its implications for treatment sequencing decisions in clinical practice.

An oncology specialist outlines their general approach to managing treatment-related atrial fibrillation in patients receiving BTK inhibitor therapy, incorporating insights from recent clinical data to inform their management strategies.

Medical experts deliberate on strategies for managing newly developed or exacerbated hypertension in patients undergoing treatment with BTK inhibitors for chronic lymphocytic leukemia.

Experts analyze recent real-world evidence on treatment patterns, focusing on the strategies and outcomes of switching and sequencing therapies in chronic lymphocytic leukemia patients.

Key opinion leaders compare and contrast the most frequently observed causes of BTK inhibitor intolerance in clinical practice among patients treated with ibrutinib, acalabrutinib, or zanubrutinib.

A panel of experts examines and interprets the most recent matching-adjusted indirect comparison (MAIC) data presented at the European Hematology Association 2024 conference, focusing on the comparative analysis of the ASCEND and ALPINE trials in chronic lymphocytic leukemia treatment.

A clinician outlines their treatment strategy for relapsed/refractory chronic lymphocytic leukemia patients, emphasizing how previous treatment history influences subsequent therapy choices.

An expert in the field provides insights into current clinical trials investigating the efficacy of combined BCL-2 inhibitor and BTK inhibitor therapies.

Experts analyze the potential applications of triplet therapy (venetoclax, BTK inhibitor, and obinutuzumab) in first-line chronic lymphocytic leukemia treatment, focusing on patient subgroups most likely to benefit from this approach.

A chronic lymphocytic leukemia expert examines patient criteria for first-line doublet therapy (venetoclax plus BTK inhibitor) versus triplet therapy, while also addressing findings from the CAPTIVATE trial.

The panelists explore strategies for managing front-line chronic lymphocytic leukemia (CLL) treatment in patients with pre-existing hypertension and atrial fibrillation.

Key opinion leaders examine the use of continuous Bruton's tyrosine kinase inhibitor therapy in front-line treatment, strategies for sequencing therapies, and the potential incorporation of obinutuzumab into treatment regimens.

Leading chronic lymphocytic leukemia specialists explore strategies for selecting initial treatments, weighing the merits of fixed-duration versus continuous Bruton's tyrosine kinase inhibitor (BTKi) therapy for newly diagnosed patients.

Key opinion leaders are introduced and present a concise overview of the topics to be addressed.